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Abstract
The aim of this study was to investigate the in vitro anti-inflammatory activity ofMalva sylves-
tris extract (MSE) and fractions in a co-culture model of cells infected by Aggregatibacter acti-
nomycetemcomitans. In addition, we evaluated the phytochemical content in the extract and
fractions ofM. sylvestris and demonstrated that polyphenols were the most frequent group in
all samples studied. An in vitro dual-chamber model to mimic the periodontal structure was
developed using a monolayer of epithelial keratinocytes (OBA-9) and a subepithelial layer of
fibroblasts (HGF-1). The invasive periodontopathogen A. actinomycetemcomitans (D7S-1)
was applied to migrate through the cell layers and induce the synthesis of immune factors
and cytokines in the host cells. In an attempt to analyze the antimicrobial properties of MSE
and fractions, a susceptibility test was carried out. The extract (MIC 175 μg/mL, MBC 500μg/
mL) and chloroform fraction (MIC 150 μg/mL, MBC 250 μg/mL) were found to have inhibitory
activity. The extract and all fractions were assessed using a cytotoxicity test and results
showed that concentrations under 100 μg/mL did not significantly reduce cell viability com-
pared to the control group (p > 0.05, viability > 90%). In order to analyze the inflammatory
response, transcriptional factors and cytokines were quantified in the supernatant released
from the cells. The chloroform fraction was the most effective in reducing the bacterial coloni-
zation (p< 0.05) and controlling inflammatory mediators, and promoted the down-regulation
of genes including IL-1beta, IL-6, IL-10, CD14, PTGS, MMP-1 and FOS as well as the reduc-
tion of the IL-1beta, IL-6, IL-8 and GM-CSF protein levels (p< 0.05).Malva sylvestris and its
chloroform fraction minimized the A. actinomycetemcomitans infection and inflammation
processes in oral human cells by a putative pathway that involves important cytokines and
receptors. Therefore, this natural product may be considered as a successful dual anti-inflam-
matory–antimicrobial candidate.
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Introduction
Periodontal disease is characterized by bacterial infection associated with the presence of bio-
film, resulting in chronic inflammation of the tooth-supporting tissues and leading to progres-
sive destruction of periodontal tissue. This disease affects up to 90% of the world’s population
[1, 2]. Dental biofilm with a large quantity of gram-negative bacteria is responsible for the initi-
ation and maintenance of periodontal inflammation [3]. Aggregatibacter actinomycetemcomi-
tans has been described as an important agent of localized aggressive periodontic lesions, but is
also related to chronic periodontitis [4, 5]. In addition, A. actinomycetemcomitans and other
pathogenic microbiota including Porphyromonas gingivalis, Treponema denticola, Tannerela
forsythia trigger both innate and acquired immune responses, resulting in the progression of
periodontal disease, and promote soft tissue inflammation and destruction with consequent
bone resorption [6].
The development of new therapeutic agents that can inhibit biofilm formation and modu-
late the inflammatory response will have a major impact on the prevention and treatment of
periodontal disease [7].
Nature has been a source of medicinal products for centuries, yielding many useful drugs
[8]. A wide variety of plants are well recognized for their medicinal and nutraceutical value,
and the exploration of biodiversity from rich environments has led to the discovery of many
pharmacologically active chemicals [9, 10].Malva sylvestris is one example. Commonly known
as mallow, it is a plant native to Europe, North Africa and Asia. The ethnopharmacological lit-
erature has reported a long history of recognition for its potent anti-inflammatory, antioxidant,
anticancer and antiulcerogenic properties [11, 12]. Some reports have indicated thatM. sylves-
tris contains phytochemicals including several classes of terpenoids, including monoterpenes,
diterpenes, sesquiterpenes and norterpenes [11, 13, 14]. Since natural products do not have a
standard composition, there is increasing interest in identifying biological therapeutic potential
in new plant extracts [15]. Thus, the aim of this study was to investigate in vitro the antimicro-
bial and anti-inflammatory activity ofMalva sylvestris extract and fractions in a dual chamber
model of epithelial and subepithelial cells infected by A. actinomycetemcomitans.
Material and Methods
Preparation of the extract and fractions
Malva sylvestris leaves were purchased from a local farmer in the municipality of Princesa Isa-
bel, Paraiba (northeast Brazil) in March and April 2013. This plant is not an endangered or
protected species and was registered in the herbarium of the University of Sao Paulo (USP),
receiving an identification number (ESA voucher # 121403). Absolute ethanol (800 mL) at
room temperature was used to create extracts ofM. sylvestris leaves (100 g) using exhaustive
maceration (for 7 days). Filtration was used to obtain the ethanolic extract ofM. sylvestris
(MSE). The material was lyophilized, homogenized, weighed and stored at -20°C. The MSE
was successively partitioned using liquid-liquid extraction with hexane, chloroform, and ethyl
acetate solvents. The final residue obtained after ethyl acetate fractionation was totally soluble
in water and thus was called the aqueous fraction (AF)[16]. The extract (MSE), chloroform
fraction (CLF) and aqueous fraction were re-suspended in 1% ethanol and used in the biologi-
cal assays.
Determination of total flavonoid, phenol and condensed tannin content. For the flavo-
noid determination, the aluminum chloride method was used. Total flavonoid contents were
calculated using quercetin for the calibration curve. The absorbance was measured at 425 nm
with a microplate reader (SpectraMax M5, Molecular Devices Sunnyvale, CA, USA). The
Malva sylvestris Inhibits Inflammatory Response in Oral Cells
PLOS ONE | DOI:10.1371/journal.pone.0140331 October 19, 2015 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
polyphenol content was measured by the Folin-Ciocalteu method and gallic acid was used as a
standard equivalent [17]. For the content of condensed tannins, a vanillin solution was added
to the extract, followed by 37% hydrochloric acid. The calibration curve was determined based
on catechin as a reference.
Bacterial Strains
The A. actinomycetemcomitans (D7S-1) was cultivated from the subgingival plaque of an Afri-
can American female patient diagnosed with generalized aggressive periodontitis. The strain
was kindly donated by Dr. Casey Chen (University of Southern California) [18]. In addition,
the following reference strains were used: Fusobacterium nucleatum ATCC 25586, Prevotella
intermedia 25611 and Porphyromonas gingivalis ATCC BAA-308.
Cell culture
Keratinocytes were processed and isolated, and the cell line established was named OBA-9
[19]. The cell line was kindly donated by Dr. Kusumoto. OBA-9 cells used in this experiment
were cultured in a specific medium for keratinocytes (Defined Keratinocyte-SFM, Life Tech-
nologies, Carlsbad, CA, USA). The human gingival fibroblasts HGF-1 (ATCC CRL-2014) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum
(Gibco, Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin and 100 μg/mL strepto-
mycin (Invitrogen Life Technologies, CA, USA). Cells were maintained in a humidified incuba-
tor at 37°C in 5% CO2.
Susceptibility testing
The susceptibility of four potential periodontopathogenic bacteria (A. actinomycetemcomitans
DS7-1, Fusobacterium nucleatum ATCC 25586, Prevotella intermedia 25611 and Porphyromo-
nas gingivalisATCC BAA-308) to MSE extract and fractions were tested. Tests were performed
according to Clinical and Laboratory Standards Institute guidelines [20]. The minimum inhibi-
tory concentration (MIC) was determined as follows. Bacteria were inoculated at a concentration
of 5 × 105 CFU/mL in 96-well microplates, using a trypticase soy broth and yeast extract medium
(TSB, YE, Difco, Franklin Lakes, NJ, USA) for A. actinomycetemcomitans and enriched with
5 μg/mL hemin and 1 μg/mL of menadione for the other microorganisms. The concentrations of
MSE and fractions ranged from 3.125 to 1000 μg/mL. The vehicle control was ethanol (final eth-
anol concentration: 1%, v/v), and the positive control was gentamicin (1 mg/mL, Sigma-Aldrich,
St. Louis, MO, USA). The plates for the evaluation of antimicrobial activity against facultative
aerobes were incubated at 37°C, 5% CO2 and the plates for evaluation of activity against strict
anaerobes were placed in an anaerobic chamber at 37°C, 10% H2, 10% CO2 and 80% N2. The
MIC was defined as the lowest concentration of MSE or fraction that allowed no visible growth,
confirmed by 0.01% resazurin dye (Promega, Madison, WI, USA). The minimum bactericidal
concentration (MBC) was determined by subculturing in trypticase soy agar (TSA, Difco, Frank-
lin Lakes, NJ, USA) or TSA containing 2 μg/mL hemin, 1 μg/mLmenadione and sheep blood
(5.0%) and 20 μL aliquots from each incubated well with a concentration equal to or greater than
the MIC. The experiments were conducted in triplicate in three independent assays.
Cell viability test
HGF-1 cells were seeded (~ 1x105 cells/mL) in a 96-well plate and incubated for 24 h at 37°C
with 5% CO2.M. sylvestris extract and fractions (0.1–1000 μg/mL) were added to the cell cul-
ture and incubated for 24 h. After the incubation time, the supernatant was discarded and the
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cells were washed with PBS (Lonza, Walkersville, MD, USA). Fresh medium and 20 μL of Cell-
Titer-Blue (Promega Corp, Madson, WI, USA) were added and incubated at 37°C and 5%
CO2. The CellTiter-Blue test is a fluorescent assay that measures cell viability via non-specific
redox enzyme activity. After incubation, the well contents were transferred to a new microplate
and the fluorescence was read in a microplate reader (SpectraMax M5 Molecular Devices Sun-
nyvale, CA, USA) with 550 nm excitation, 585 nm emission [21].
Invasion dual chamber assay
The activity of MSE and its fractions in cells infected by A. actinomycetemcomitans were inves-
tigated using an adapted dual chamber model to mimic the periodontum [22]. Keratinocytes
(OBA-9) were seeded in a transwell insert with an 8 μm pore and 0.3 cm2 culture surface (Gre-
nier Bio-One, Monroe, NC, USA) and positioned in a 24 well plate. The basal chamber was
seeded with HGF-1 fibroblasts. After 24 h the transepithelial resistance (TEER) was measured
for each cell layer using a Millicell-ERS Volt-OhmMeter (Millipore, Bedford, MA, USA). The
cell layer confluence in the transwell insert was measured to reach the optimal TEER (>150
Ohm/cm2). On day 2, an overnight A. actinomycetemcomitans culture was harvested by centri-
fugation at 900 X g for 10 min at room temperature and incubated in the dual chamber with
KSFM culture medium (~1x106 CFU/mL) passing through the upper layer of cells (OBA-9)
and reaching the bottom layer (HGF-1) for 2h. Extracellular, unattached bacteria were
removed by washing with saline buffer (PBS) two times. After this initial incubation, epithelial
and subepithelial cell layers were incubated with gentamicin 100 μg/mL (Sigma, St Louis, MO,
USA) to kill the extracellular bacteria. The medium was removed and washed with saline
buffer. Fresh new culture medium was added and the culture was treated with MSE or fractions
at a concentration of 75 μg/mL. In light of the dose-dependent effects of MSE and CLF treat-
ments, this concentration was determined to be the highest concentration that possessed anti-
microbial activity but was still non-cytotoxic after an exposure time of 24 h.
Sample analysis
Antimicrobial activity. The antimicrobial activity of MSE and fractions in the co-culture
model was accessed after 24 h of treatment. Aliquots of 20 μL were cultured from each sample
in TSB-YE plates to determine the CFU/mL and quantify the numbers of viable bacterial cells.
Analysis using the RT2 Profiler PCR Array
One microgram of RNA was converted in cDNA using RT2 First Strand Kit (Qiagen, Valencia,
CA, USA) according to the manufacture’s instructions. 84 genes were analyzed using inflam-
matory response & Autoimmunity Array RT2 profiler (Qiagen Sabiosciences, Valencia, CA,
USA) with buffers supplied by the manufacturer. The full list of genes detected by the SYBR
Green-optimized primer assays is shown in (Table 1). A reaction mixture was prepared using
102 μL cDNA, 1248 μL water and 1350 μL SYBR Green/ROX. Analysis was performed using
the Sabioscences web portal (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php),
according to the 2ΔΔCT method. DataSet is assigned a GEO accession number GSE72443.
Quantitative Real-Time PCR. Quantitative PCR (qPCR) was performed to evaluate the
possible effects of the A. actinomycetemcomitans invasion in the lower chamber compartment
upon reaching the subepithelial cells (HGF-1). In addition, we aimed to analyze genes related
to the inflammation process to verify whether MSE and fractions could promote some biologi-
cal activity in the infection process. RNA was isolated from cell culture after 24h of treatment
using the RNeasy Mini Kit (Qiagen; Valencia, CA, USA). Purity and quantity of RNA were
measured in the NanoPhotometer P360 (Implen; Westlake Village, CA, USA). RNA sample
has been treated with DNase. Reverse transcription of RNA to cDNA was performed using the
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QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. Based on PCR array analysis, genes were selected that presented significant
levels of down-regulation (Quantitech Primers, Qiagen). The threshold was manually adjusted
within the logarithmic curve above the background level and below the plateau phase. A com-
parative Ct method was used to calculate the relative gene number. The relative gene copy
number was calculated using the 2ΔΔCT method.
Cytokine assay. Cytokine assays were performed on all samples using specific enzyme-
linked immunosorbent assay (ELISA) kits (Qiagen, Valencia, CA, USA). The cytokines were
selected in order to confirm the encoded genes that exhibited down-regulation in the gene
expression analyses. The concentration of IL-1alpha, IL-1beta, IL6, IL8, IL10 and GM-CSF
were measured according to the manufacturer’s instructions.
Results
Chemical analysis
Determination of total flavonoid, phenol and condensed tannin content. The phyto-
chemical characterization revealed that the total polyphenol contents of MSE, CLF and AF
were 38%, 26% and 22% gallic acid equivalents, respectively. Tannin represented 0.02%, 0.54%
and 0.8% catechin equivalent in MSE, CLF and AF respectively; flavonoid content was 2.7%,
7% and 5.6% quercetin equivalent in MSE, CLF and AF respectively.
Susceptibility testing
Table 2 shows the MIC and the MBC values of MSE and fractions screened for different peri-
odontopathogenic bacteria. The results demonstrated that MSE and CLF had inhibitory
Table 1. The Human Inflammatory Response & Autoimmunity RT² Profiler PCR Array. This assay profiles 84 key genes involved in autoimmune and
inflammatory immune responses. It profiles genes related to inflammatory cytokines and chemokines as well as their receptors and also genes related to the
metabolism of cytokines and those involved in cytokine-cytokine receptor interactions.
Functional Gene Grouping Subgroup Gene symbol
Cytokine Chemokines CCL11 (eotaxin), CCL13 (MCP-4), CCL16 (HCC-4), CCL17 (TARC), CCL19, CCL2 (MCP-1),
CCL21 (MIP-2), CCL22 (MDC), CCL23 (MPIF-1), CCL24 (MPIF-2), (Eotaxin-2), CCL3 (MIP-1A),
CCL4 (MIP-1B), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (MCP-2), CXCL1 (GRO1, GROa,
SCYB1), CXCL10 (INP10), CXCL2 (GRO2, GROb, SCYB2), CXCL3, CXCL5 (ENA-78, LIX),
CXCL6 (GCP-2), CXCL9 (MIG).
Interleukins IL10, IL15, IL17A, IL18, IL1A, IL1B, IL1RN, IL22, IL23A, IL5, IL6, CXCL8
Other Cytokines IL10, IL15, IL17A, IL18, IL1A, IL1B, IL1RN, IL22, IL23A, IL5, IL6, CXCL8, CSF1(MCSF), FASLG
(TNFSF6), LTB, TNFSF14
Cytokines Receptors Cytokine
Receptor
IL10RB, IL1R1, IL1RAP, IL23R,IL6R.
Chemokine
Receptors
CCR1, CCR2, CCR3, CCR4, CCR7, CXCR1 (IL8RA), CXCR2 (IL8RB), CXCR4.
Cytokine Metabolism - IL10, IL18, TLR1, TLR3, TLR4, TLR6
Cytokine-Mediated Signaling - CCL2 (MCP-1), CCL5 (RANTES), CCR1, CCR2, IFNG, IL1A, IL1B, IL1R1, IL1RN, IL5, IL6,
IL6R, MYD88, RIPK2, TNF
Acute-phase response CEBP, CRP, PTGS2
Chronic Inflammatory
Response
- CCL11 (eotaxin), CCL5 (RANTES), IL1B, LTA (TNFB), TNF
Humoral Immune Response - C3, CCL16 (HCC-4), CCL2 (MCP-1), CCL22 (MDC), CCL3 (MIP-1A), CCL7 (MCP-3), CCR2,
CCR7, CD40 (TNFRSF5), IL10, IL18, IL1B, IL6, ITGB2, LY96 (MD-2), NFKB1.
Regulation of the
inflammatory response
- BCL6, C3AR1, CD14, CD40LG, FOS, IL9, KNG91, NOS2, NR3C1, SELE, TIRAP, TLR3, TLR5,
TLR7, TOLLIP
doi:10.1371/journal.pone.0140331.t001
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activity for the all microorganisms tested: A. actinomycetemcomitans, Fusobacterium nuclea-
tum, Prevotella intermedia and Porphyromonas gingivalis. CLF was the most potent, with an
MIC against A. actinomycetemcomitans of 150 μg/mL, an MIC against F. nucleatum of 500 μg/
mL and an MIC against P. intermedia of 125 μg/mL. The MSE had the lowest MIC against P.
gingivalis (15.6 μg/mL). AF had no inhibitory activity against any of the bacteria tested. Genta-
micin was used as the positive control (10 μg/mL).
Cell viability test
The cytotoxicity of the extract and all fractions was assessed at concentrations of 0.1, 1, 10, 100
and 1000 μg/mL. AF did not affect the cell viability (p>0.05) at any of the concentrations tested
when compared to the control group (non-treated). MSE and CLF reduced the number of via-
ble cells at concentrations of 100 μg/mL and 1000 μg/mL (p<0.05). MSE and CLF were non-
toxic at concentrations of 0.1, 1 and 10 μg/mL (Fig 1).
Invasion dual chamber assay
MSE, CLF and AF activity in the co-culture model: susceptibility test, ELISA and gene
expression. A viability test was used to determine the effects of the treatments and select the
best culture conditions after A. actinomycetemcomitans infection. In addition, cells were ana-
lyzed for the ability to form an impervious epithelial layer by measuring the TEER. Dose-
dependent antimicrobial effects were found for MSE and CLF treatment but high concentra-
tions ( 100 μg/mL) were toxic for the cells; thus we tested the highest non-toxic concentration
for all the samples. A sub-MIC concentration of 75 μg/mL was established. Results confirmed
that treatment with 75 μg/mL MSE or CLF did not significantly affect the percentage of viable
cells or the integrity of the tight epithelial conjunction (Fig 2).
In order to confirm the invasion assay of A. actinomycetemcomitans we first recovered the
cultures from the dual compartment chambers. The time 0 h represents this time point at
which the CFU quantification was performed after 2h infection period followed by 1h gentami-
cin treatment. There were no differences among the groups in the amount of internalized bac-
teria at time 0h (p>0.05). Twenty-four hours after the infection was initiated, the groups
treated with MSE and AF had no ability to reduce or eliminate the invasion in the host cells;
however, the number of microorganisms in the CLF group was reduced significantly compared
to the control vehicle group (p<0.05)(Fig 3).
Analysis Using the RT2 Profiler PCR Array
Alterations in mRNA transcript levels for all treatment groups were initially analyzed using the
RT2 Profiler PCR Array and 84 genes were screened and analyzed using the SABiosciences web
portal software. The transcriptional profile in the lower chamber cell lines after 24 hours
Table 2. Minimum inhibitory concentration (MIC) andminimum bactericidal concentration (MBC). MIC and MBC for the ethanolic extract ofMalva syl-
vestris and its chloroform and aqueous fraction against four different periodontopathogens: Aggregatibacter actinomycetemcomitans D7S1, Fusobacterium
nucleatum ATCC 25586, Prevotella intermedia ATCC 25611 and Porphyromonas gingivalis ATCC BAA-308. The highest concentration evaluated was
1000 μg/mL and the minus symbol (-) means no inhibitory activity.
Extract/
fraction
A.
actinomycetemcomitans
F. nucleatum P. intermedia P. gingivalis
MIC MBC MIC MBC MIC MBC MIC MBC
MSE 175 500 1000 - 250 - 15.6 125
CLF 150 250 500 - 125 500 62.5 1000
AF - - - - - - - -
doi:10.1371/journal.pone.0140331.t002
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invasion assay is showed on Table 3. It was found a down-regulation of 6 different genes
among 84 target genes. For the fold changes, values less than 1 are considered down regulated.
Quantitative Real-Time PCR. The following genes were analyzed using qRT-PCR: IL-
1alpha, IL-1beta, IL-6, IL-8, IL-10, CD14, PTGS, FOS, BCL6 and MMP-1. The reference con-
trol gene was GAPDH and the calibrator for the 2ΔΔCT method was the non-treated control
group. A minus-reverse transcriptase control was included in all qPCR experiments.
Fig 1. Cytotoxicity test.Cytotoxic effect of MSE, CLF and AF on fibroblasts HGF-1 cells. Data are expressed as mean ± SEM using one-way analysis of
variance (ANOVA) followed by Dunnet’s multiple comparison tests as compared to non-treated. The level of statistical significance was set at 0.05.
doi:10.1371/journal.pone.0140331.g001
Fig 2. Cytotoxicity effect in the dual chamber model.Cytotoxic effects of MSE, chloroform and aqueous
fraction on fibroblast HGF-1 and keratinocyte OBA-9 cell lines were found after 24 h hours of invasion by A.
actinomycetemcomitans. Data are expressed as mean ± SEM using one-way analysis of variance (ANOVA)
followed by Dunnet’s multiple comparison tests as compared to the control group (non-treated). The level of
statistical significance was set at 0.05.
doi:10.1371/journal.pone.0140331.g002
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The results showed that cells invaded by A. actinomycetemcomitans and treated with MSE
had statistically significant down-regulation of the genes IL6, IL8, CD14 compared to the con-
trol group (non-infected cells) (p<0.05). The chloroform fraction down-regulated the gene
expression of IL-1beta, IL6, IL10, PTGS, CD14, PTGS, FOS and BCL6 (p<0.05) compared to
the control group. The group treated with AF showed a down-regulation of mRNA transcript
levels for the genes IL-1alpha, IL-1beta, CD14, PTGS and FOS (p<0.05) (Fig 4).
Fig 3. Comparison of colony-forming units.Comparison of colony-forming units (CFU/mL) among groups treated with MSE, CLF and AF after A.
actinomycetemcomitans infection. Data are expressed as mean ± SEM using one-way analysis of variance (ANOVA) followed by Dunnet’s multiple
comparison tests as compared to vehicle control. The level of statistical significance was set at 0.05.
doi:10.1371/journal.pone.0140331.g003
Table 3. The Human Inflammatory Response & Autoimmunity RT² Profiler PCRArray. Genes in the inflammatory pathway down-regulated by the treat-
ments with MSE, CLF and AF.
Symbol Gene Gen Bank Fold changes
MSE CLF AF
BCL6 B-cell CLL/lymphoma 6 NM_001130845 0.37 0.45 0.68
CD14 CD14 molecule NM_000591 0.64 0.63 0.57
FOS FBJ murine osteosarcoma viral oncogene homolog NM_005252 0.23 0.05 0.81
IL-1beta Interleukin 1, beta NM_000576 0.57 0.64 0.57
IL-6R interleukin 6 receptor NM_000565 0.07 0.08 0.29
IL-8 Interleukin 8 NM_000584 0.36 0.48 0.89
doi:10.1371/journal.pone.0140331.t003
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Fig 4. Gene expression analysis of lower chamber co-culture invasion assay. The expression levels of
IL-1alfa, IL-1beta, IL-6, IL-8, IL-19, CD14, PTGS, MMP-1, FOS, BCL2 were evaluated and compared to the
control (non-infected cells). Quantification of the relative transcript amounts was performed using qPCR with
50 ng of each cDNA. Data quantification was performed using the 2ΔΔCTmethod. Statistical analyses
included one-way ANOVA followed by Dunnet’s post-hoc tests. A significance level of p < 0.05 (*) indicates
differences from the vehicle group.
doi:10.1371/journal.pone.0140331.g004
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Cytokine assay. The concentrations of IL-1 alpha, IL-1beta, IL-6, IL-8, IL-10 and
GM-CSF were quantified by ELISA to confirm whether the proteins encoded by the down-reg-
ulated genes were found at reduced levels in the supernatant. MSE reduced the expression of
IL-6 in the infected cells compared to the vehicle control group (p<0.05). Significant differ-
ences in the levels of a number of cytokines were found between the CLF and control groups.
Specifically, reduced expression levels were observed for the cytokines IL-1beta, IL-6, IL-8 and
GM-CSF (reductions of 32%, 80, 3%, 30, 58 and 4% compared to the vehicle control, respec-
tively). Infected cells expressed low levels of IL-1 alpha when treated with the AF, a decrease of
31% compared to the vehicle control group (Fig 5).
Discussion
Periodontal disease is an oral infectious inflammatory disease and the most common human
chronic disorder [23]. The relationship between this disease and many systemic diseases
(including cardiovascular disease, diabetes, adverse pregnancy outcomes and others) is well
recognized [24, 25]. Based on current knowledge of inflammation pathways, it appears that
natural products may be a good source for developing multi-target drugs with activity against
the microorganisms responsible for periodontal disease [26, 27].
For this study, we evaluated the toxicity, antimicrobial and anti-inflammatory activity of
compounds naturally occurring in the plantM. sylvestris [28]. A screening assay simulating the
effect of A. actinomycetemcomitans, a species known to be associated with periodontal disease,
was used to model the infection of epithelial and subepithelial cell lines [22]. These results con-
firmed the internalization of the bacteria, indicating the possible activation of the membrane
and intracellular receptors [29]. Transcriptional factors and cytokines identified in the infec-
tion process suggested signaling and host response pathways were involved in the bacteria chal-
lenge and during the treatment withM. sylvestris extract and fractions.
The antimicrobial susceptibility test showed that MSE and CLF had activity not only against
A. actinomycetemcomitans but also against other periodontopathogens (F. nucleatum, P. gingi-
valis and P. intermedia) that are implicated in the development and virulence of periodontal
disease [1]. In addition, this demonstrates thatM. sylvestris works against both microaerophiles
and anaerobes. In the literature, it has been shown that the ethanolic extract ofM. sylvestris is
effective as a bacteriostatic agent against methicillin-resistant S. aureus (I50 32 μg/ml) [30],
and moderate to low activity was reported against strains of Helicobacter pylori (MIC ranged
from 0.625 to>5.0 mg/mL)[31]; moreover, the aqueous fraction was reported to have anti-fun-
gal activity, though not against Candida albicans [32]. Overall, though antimicrobial effects of
M. sylvestris have been reported in the literature for a few microorganisms [30, 31, 32] these
studies used different extract preparations and the majority were based on agar-diffusion tests,
making inter-study comparisons difficult.
Our findings also demonstrate that the bioguided fractionation was successful and may be a
model for bioprospecting new drugs, as long as the active fraction (CLF) presented enhanced
antimicrobial activity relative to the unfractionated extract. In addition, our data describe the
cytotoxicity of the extract and fractions in vitro to provide better estimation of the potential of
the compound as favorable therapeutic agent. The viability test showed that the CLF fraction
was non-toxic at concentrations up to 100 μg/mL and AF had no toxic effects at any of the con-
centrations tested. The LD50 of the extract for cell lines OBA-9 and HGF (250 μg/mL and
210 μg/mL, respectively) gave insight into the safe concentrations for use in the biological
assays.M. sylvestris is widely known as a food or condiment and has been used for millennia in
traditional medicine; however, only one in vivo test of its toxicity has been reported in the liter-
ature [33].
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Fig 5. Cytokine assay.Quantification of IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 and GM-CSF in the co-culture supernant after 24h of A.
actinomycetemcomitans invasion. Cells were treated with 75μg/mL of MSE and fractions and bacteria inocula were established at 2x106 CFU/mL. Data are
expressed as mean±SD, n = 6. Symbols indicate statistical differences (p<0.05, Dunnet’s test). # indicates p<0.05 compared to non-treated group; *
indicates p<0.05 compared to vehicle group.
doi:10.1371/journal.pone.0140331.g005
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The bacterial products from A. actinomycetemcomitans affected the cell immune response
and increased the production of local cytokines. All the treatments tested affected different sig-
naling pathways. Upon treatment with the aqueous fraction, both the IL-1alpha gene and pro-
tein expression levels were reduced. The pro-inflammatory cytokine IL-1 and tumor necrosis
factor alpha (TNF alpha) are modulators of the host response to microbial infection. It has pre-
viously [34] been demonstrated that IL-1 specific marker is a strong indicator of susceptibility
to severe periodontal disease in adults. Furthermore, it has been established that IL-1 is
involved in the induction of bone resorption by promoting the differentiation of osteoclast pre-
cursors in active osteoclasts [35].
A statistical reduction of IL-6 gene expression and protein levels were found after treatment
with the chloroform fraction (CLF). The higher expression levels of IL-6 in untreated peri-
odontal disease might induce an increase in matrix metalloproteinases (MMPs) that are related
to tissue destruction [36, 37]. IL-6 has been reported as a principal regulator in the acute phase
of inflammation and may promote osteoclastogenesis by increasing tRANKL expression [38].
In addition, the CLF treatment regulated the expression of other immunomodulatory genes
(CD14, MMP1 and FOS), which indicates an effect on more than one signaling pathway and
may result in a good therapeutic outcome. Finding compounds that trigger CD14 or toll-like
receptors (TLRs) is potentially useful in periodontal disease. The binding of lipopolysaccha-
rides (LPS) with CD14 might induce the temporary activation of many protein kinases and the
phosphorylation of intracellular proteins essential for LPS activation in monocytes/macro-
phages [39].
The MSE could regulate the transcription of IL-8 but not the same cytokine expression. The
answer to the question of how genomic information can be processed differently to produce a
specific cellular proteome to date remains unanswered [40, 41]. The literature has been demon-
strated thatM. sylvestrismay regulated the expression of cytokines in the inflammatory pro-
cess. In a pre-clinical study, important anti-inflammatory action of the hydroalcoholic extract
was found to interfere with the production of IL-1beta and consequently block leukocyte
migration [42]. Furthermore, the aqueous extract ofM. sylvestris was found to have an immu-
nomodulatory property, acting as a macrophage activators and promoting both IL-12 and
(IFN) interferon transcripts [42]. Overall, the literature and present data highlight the biologi-
cal activity ofM. sylvestris in treating inflammation.
The phytochemical investigation ofM. sylvestris showed a high occurrence of phenolic com-
pounds in all studied extracts and fractions. This is consistent with a previous report [14], in
which 4-hydroxybenzoic acid, 4-methoxybenzoic acid, 4-hydrocycinnamic acid and tyrosol
were isolated fromM. sylvestris. Furthermore, the interest in phenolic compounds has
increased in recent years due to their possible implications for human heath, such as in treating
and preventing cancer, cardiovascular disease and other pathologies [11]. Overall, phenolic
compounds are particularly potent natural products with a wide range of biological properties
known in the literature that could be used extensively in dentistry.
The results of the present study showed that the low-polarity fraction CLF has relevant dual
activity, simultaneously controlling infection and inflammation processes. Thus,M. sylvestris
may be considered as a potential drug candidate for use as a new therapeutic approach in the
treatment of the periodontal disease.
Conclusion
In our study we found thatMalva sylvestris and its chloroform fraction were able to minimize
the infection and inflammation process in oral human cells by a putative pathway that may
involve the antimicrobial effect and modulation of cytokines and receptors. Therefore, this
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natural product may be considered as a successful dual anti-inflammatory–antimicrobial
candidate.
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